NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

生物來源創傷護理產品的全球市場的預測 ∼2023年:生物來源皮膚替代品 (生物合成產品)、局部劑

Wound Care Biologics Market by Product (Biological Skin Substitutes (Biosynthetic Products), Topical Agents), Wound Type (Diabetic Foot Ulcer, Pressure Ulcers, Surgical & Traumatic Wound), End User (Hospitals, Burn Centers) - Global Forecast to 2023

出版商 MarketsandMarkets 商品編碼 648567
出版日期 內容資訊 英文 125 Pages
訂單完成後即時交付
價格
生物來源創傷護理產品的全球市場的預測 ∼2023年:生物來源皮膚替代品 (生物合成產品)、局部劑 Wound Care Biologics Market by Product (Biological Skin Substitutes (Biosynthetic Products), Topical Agents), Wound Type (Diabetic Foot Ulcer, Pressure Ulcers, Surgical & Traumatic Wound), End User (Hospitals, Burn Centers) - Global Forecast to 2023
出版日期: 2018年06月01日內容資訊: 英文 125 Pages
簡介

全球生物來源創傷護理產品的市場在預測期間內預計以9.8%的年複合成長率發展,預計從2018年的14億2000萬美元,成長到2023年的22億6000萬美元的規模。糖尿病足部潰傷的罹患率上升,老年人口增加,燙傷患者增加等要素促進該市場的成長。

本報告提供全球生物來源創傷護理產品的市場調查,市場定義和概要,市場成長的影響因素及市場機會分析,各產品、創傷類型、終端用戶、地區/主要國家趨勢與市場規模的變化與預測,競爭環境,主要企業簡介等彙整。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

第5章 市場概要

  • 簡介
  • 皮膚替代品的償付方案 (美國)
  • 市場動態
    • 成長推動因素
    • 阻礙成長要素
    • 市場機會

第6章 生物來源創傷護理產品市場分析、預測:各產品

  • 簡介
  • 生物來源皮膚替代品
    • 人體組織來源的產品
    • 無細胞動物來源的產品
    • 生物合成產品
  • 局部劑

第7章 生物來源創傷護理產品市場分析、預測:各創傷類型

  • 簡介
  • 潰瘍
    • 糖尿病足部潰傷
    • 靜脈潰瘍
    • 褥瘡
    • 其他
  • 手術疤痕、外傷性創傷
  • 燙傷

第8章 生物來源創傷護理產品市場分析、預測:各終端用戶

  • 簡介
  • 醫院
  • 門診病人手術中心
  • 燙傷中心、創傷診療所

第9章 生物來源創傷護理產品市場分析、預測:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 其他
  • 其他地區

第10章 競爭環境

  • 概要
  • 市場佔有率排行榜
  • 排行榜前幾名企業
  • 市場佔有率分析 (美國)
  • 競爭模式
    • 產品的投入、核准
    • 協定
    • 收購
    • 擴張
    • 其他

第11章 企業簡介

  • SMITH & NEPHEW
  • MOLNLYCKE HEALTH CARE AB (INVESTOR AB)
  • INTEGRA LIFESCIENCES
  • WRIGHT MEDICAL
  • MIMEDX GROUP
  • VERICEL
  • ANIKA THERAPEUTICS
  • OSIRIS THERAPEUTICS
  • ORGANOGENESIS
  • KERECIS
  • SOLSYS MEDICAL
  • ACELL
  • MARINE POLYMER TECHNOLOGIES

第12章 附錄

目錄
Product Code: MD 6335

"The wound care biologics market is projected to grow at a CAGR of 9.8% during the forecast period."

The wound care biologics market is expected to reach USD 2.26 billion by 2023 from USD 1.42 billion in 2018, at a CAGR of 9.8%. Market growth is mainly driven by factors such as the increasing incidence of diabetic foot ulcers, increasing geriatric population, and increasing burn injuries globally. On the other hand, the high cost of wound care biologics and the higher rejection rate associated with skin grafts & substitutes will restrain the growth of this market.

"The biological skin substitute segment is anticipated to grow at the fastest rate in the next five years."

Based on product, the wound care biologics market is segmented into biologic skin substitutes and topical agents. The biological skin substitutes segment is estimated to account for the largest share in 2018 and grow at the highest rate from 2018 to 2023. The rising incidence of hard-to-heal wounds and their growing adoption (due to their high efficacy) are driving the growth of this product segment. The biological skin substitutes segment is further categorized into human donor tissue-derived products, acellular animal-derived products, and biosynthetic products.

"Asia Pacific is estimated to grow at the highest CAGR during the study period."

Geographically, the wound care biologics market was dominated by North America, followed by Europe in 2017. The Asia Pacific market is estimated to register the highest growth during the forecast period primarily due to the presence of a large patient population, increasing penetration of key market players, and the large number of research and development activities for wound care biologic products.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1-35%, Tier 2-22% and Tier 3- 43%
  • By Designation: C-level-15%, Director-level-32%, Others-53%
  • By Region: North America-34%, Europe-27%, Asia Pacific-23%, Rest of the World-16%

The major players in this market are: Smith & Nephew (UK), Molnlycke Health Care AB (Sweden), Integra LifeSciences Corporation (US), Wright Medical (US), MiMedx Group (US), Vericel Corporation (US), Anika Therapeutics (US), Osiris Therapeutics (US), Organogenesis (US), Kerecis (Iceland), Solsys Medical (US), ACell (US), and Marine Polymer Technologies, Inc. (US).

Research Coverage:

The report analyses the wound care biologics market by product, wound type, method, end user, and region. Apart from a comprehensive geographic product analysis and market sizing, the report also provides a competitive landscape that covers growth strategies adopted by industry players over the last three years. In addition, the company profiles include product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market. Market research data, current market size, and forecast of the future trends will help key market players and new entrants make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output to remain successful.

Key Benefits of Buying the Report:

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms garner greater market shares. Firms purchasing the report can use one or a combination of the below mentioned five strategies for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the wound care biologics market
  • Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the wound care biologics market
  • Competitive Assessment: In-depth assessment of the market strategies, geographic, and business segments and product portfolios of the leading players in the wound care biologics market
  • Market Development: Comprehensive information about emerging markets. This report analyses the market for various wound care biologics across geographies
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the wound care biologics market.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
    • 1.2.1. MARKETS COVERED
    • 1.2.2. YEARS CONSIDERED FOR THE STUDY
  • 1.3. CURRENCY
  • 1.4. LIMITATIONS
  • 1.5. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. SECONDARY DATA
    • 2.1.1. KEY DATA FROM SECONDARY SOURCES
  • 2.2. PRIMARY DATA
    • 2.2.1. KEY DATA FROM PRIMARY SOURCES
  • 2.3. MARKET SIZE ESTIMATION
    • 2.3.1. BOTTOM-UP APPROACH
    • 2.3.2. TOP-DOWN APPROACH
  • 2.4. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. WOUND CARE BIOLOGICS MARKET OVERVIEW
  • 4.2. GEOGRAPHIC ANALYSIS: WOUND CARE BIOLOGICS MARKET, BY PRODUCT (2018)
  • 4.3. GEOGRAPHIC SNAPSHOT OF THE WOUND CARE BIOLOGICS MARKET
  • 4.4. WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. REIMBURSEMENT SCENARIO FOR SKIN SUBSTITUTES IN THE US
    • 5.2.1. GENERAL CRITERIA COVERED
    • 5.2.2. APLIGRAF, THERASKIN, AND EPIFIX
    • 5.2.3. DERMAGRAFT
    • 5.2.4. INTEGRA
  • 5.3. MARKET DYNAMICS
    • 5.3.1. DRIVERS
      • 5.3.1.1. Rising incidences of burn injuries
      • 5.3.1.2. Rapid growth in the geriatric population
      • 5.3.1.3. Growing incidence of ulcers and target conditions
      • 5.3.1.4. Innovation in wound care biologics
      • 5.3.1.5. Awareness programs for wound care treatment and management
    • 5.3.2. MARKET RESTRAINTS
      • 5.3.2.1. High cost of wound treatment and wound care biologics
      • 5.3.2.2. Risk of skin substitute failure
    • 5.3.3. MARKET OPPORTUNITIES
      • 5.3.3.1. Increasing research on advanced wound treatments
      • 5.3.3.2. 3D skin printing

6. WOUND CARE BIOLOGICS MARKET, BY PRODUCT

  • 6.1. INTRODUCTION
  • 6.2. BIOLOGICAL SKIN SUBSTITUTES
    • 6.2.1. HUMAN DONOR TISSUE-DERIVED PRODUCTS
    • 6.2.2. ACELLULAR ANIMAL-DERIVED PRODUCTS
    • 6.2.3. BIOSYNTHETIC PRODUCTS
  • 6.3. TOPICAL AGENTS

7. WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE

  • 7.1. INTRODUCTION
  • 7.2. ULCERS
    • 7.2.1. DIABETIC FOOT ULCERS
    • 7.2.2. VENOUS ULCERS
    • 7.2.3. PRESSURE ULCERS
    • 7.2.4. OTHER ULCERS
  • 7.3. SURGICAL & TRAUMATIC WOUNDS
  • 7.4. BURNS

8. WOUND CARE BIOLOGICS MARKET, BY END USER

  • 8.1. INTRODUCTION
  • 8.2. HOSPITALS
  • 8.3. AMBULATORY SURGICAL CENTERS
  • 8.4. BURN CENTERS AND WOUND CLINICS

9. WOUND CARE BIOLOGICS MARKET, BY REGION

  • 9.1. INTRODUCTION
  • 9.2. NORTH AMERICA
    • 9.2.1. US
    • 9.2.2. CANADA
  • 9.3. EUROPE
    • 9.3.1. UK
    • 9.3.2. GERMANY
    • 9.3.3. FRANCE
    • 9.3.4. ROE
  • 9.4. ASIA PACIFIC
    • 9.4.1. CHINA
    • 9.4.2. JAPAN
    • 9.4.3. REST OF ASIA PACIFIC
  • 9.5. REST OF THE WORLD

10. COMPETITIVE LANDSCAPE

  • 10.1. OVERVIEW
  • 10.2. MARKET SHARE RANKING, 2017
  • 10.3. TOP RANKING COMPANIES IN THE WOUND CARE BIOLOGICS MARKET
  • 10.4. WOUND CARE BIOLOGICS MARKET SHARE ANALYSIS IN THE US, 2017
  • 10.5. COMPETITIVE SCENARIO
    • 10.5.1. PRODUCT LAUNCHES AND APPROVALS
    • 10.5.2. AGREEMENTS
    • 10.5.3. ACQUISITIONS
    • 10.5.4. EXPANSIONS
    • 10.5.5. OTHER DEVELOPMENTS

11. COMPANY PROFILES (Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

  • 11.1. SMITH & NEPHEW
  • 11.2. MOLNLYCKE HEALTH CARE AB (INVESTOR AB)
  • 11.3. INTEGRA LIFESCIENCES
  • 11.4. WRIGHT MEDICAL
  • 11.5. MIMEDX GROUP
  • 11.6. VERICEL
  • 11.7. ANIKA THERAPEUTICS
  • 11.8. OSIRIS THERAPEUTICS
  • 11.9. ORGANOGENESIS
  • 11.10. KERECIS
  • 11.11. SOLSYS MEDICAL
  • 11.12. ACELL
  • 11.13. MARINE POLYMER TECHNOLOGIES

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

12. APPENDIX

  • 12.1. INSIGHTS FROM INDUSTRY EXPERTS
  • 12.2. DISCUSSION GUIDE
  • 12.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 12.5. AVAILABLE CUSTOMIZATIONS
  • 12.6. RELATED REPORTS
  • 12.7. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: MAJOR SKIN SUBSTITUTES AVAILABLE IN THE WORLD MARKET
  • TABLE 2: INCREASE IN AGING POPULATION, BY REGION, 2015 VS. 2050 (MILLION)
  • TABLE 3: PREVALENCE OF CHRONIC WOUNDS IN THE AGING POPULATION
  • TABLE 4: AGE-SPECIFIC PREVALENCE OF DIABETIC FOOT ULCERS, BY GENDER
  • TABLE 5: PREVALENCE OF DIABETIC FOOT ULCERS, 2016
  • TABLE 6: LIST OF COMMERCIALLY AVAILABLE SKIN SUBSTITUTES, THEIR INDICATIONS, AND SUPPORTING EVIDENCE FOR USE IN CHRONIC WOUNDS
  • TABLE 7: RECENTLY LAUNCHED TECHNOLOGICALLY WOUND CARE BIOLOGICS PRODUCTS
  • TABLE 8: AWARENESS INITIATIVES RELATED TO WOUND CARE BIOLOGICS
  • TABLE 9: AVERAGE COST OF DIABETIC FOOT ULCER MANAGEMENT (WAGNER CLASSIFICATION) IN THE US
  • TABLE 10: COMPARISON OF OUTCOMES (STSG VS. FTSG PATIENTS)
  • TABLE 11: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 12: BIOLOGICAL SKIN SUBSTITUTES COMMERCIALIZED FOR WOUND TREATMENT
  • TABLE 13: WOUND CARE BIOLOGICS MARKET FOR SKIN SUBSTITUTES, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 14: WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 15: COMMERCIALIZED HUMAN DONOR TISSUE-DERIVED PRODUCTS
  • TABLE 16: HUMAN DONOR TISSUE-DERIVED PRODUCTS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 17: COMMERCIALIZED ACELLULAR ANIMAL-DERIVED PRODUCTS
  • TABLE 18: ACELLULAR ANIMAL-DERIVED PRODUCTS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 19: WOUND CARE BIOLOGICS MARKET FOR BIOSYNTHETIC PRODUCTS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 20: WOUND CARE BIOLOGICS MARKET FOR TOPICAL AGENTS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 21: COMMON COMPONENTS OF WOUND CARE BIOLOGICS
  • TABLE 22: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2016-2023 (USD MILLION)
  • TABLE 23: MEDICALLY NECESSARY BIOENGINEERED SKIN SUBSTITUTES
  • TABLE 24: WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 25: WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 26: PREVALENCE RATE OF DIABETIC FOOT ULCERS IN MAJOR COUNTRIES (2016)
  • TABLE 27: AVERAGE TREATMENT COST FOR DIABETIC FOOT ULCERS IN THE US (2015)
  • TABLE 28: WOUND CARE BIOLOGICS MARKET FOR DIABETIC FOOT ULCERS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 29: WOUND CARE BIOLOGICS MARKET FOR VENOUS ULCERS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 30: WOUND CARE BIOLOGICS MARKET FOR PRESSURE ULCERS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 31: COMMERCIALLY AVAILABLE WOUND CARE BIOLOGIC PRODUCTS FOR OTHER ULCERS
  • TABLE 32: WOUND CARE BIOLOGICS MARKET FOR OTHER ULCERS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 33: WOUND CARE BIOLOGICS MARKET FOR SURGICAL & TRAUMATIC WOUNDS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 34: AVERAGE HOSPITAL ADMISSIONS FOR THE TREATMENT OF BURN INJURIES (2015)
  • TABLE 35: SKIN REPLACEMENTS COMMERCIALIZED FOR THE TREATMENT OF BURNS
  • TABLE 36: WOUND CARE BIOLOGICS MARKET FOR BURNS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 37: WOUND CARE BIOLOGICS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 38: WOUND CARE BIOLOGICS MARKET FOR HOSPITALS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 39: PRICE ASSESSMENT OF WOUND CARE BIOLOGICS IN AMBULATORY SURGICAL CENTERS IN THE US
  • TABLE 40: WOUND CARE BIOLOGICS MARKET FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 41: WOUND CARE BIOLOGICS MARKET FOR BURN CENTERS AND WOUND CLINICS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 42: WOUND CARE BIOLOGICS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 43: NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 44: NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 45: NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2016-2023 (USD MILLION)
  • TABLE 46: NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 47: MAJOR SKIN SUBSTITUTES LAUNCHED IN THE US
  • TABLE 48: US: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 49: US: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2016-2023 (USD MILLION)
  • TABLE 50: US: WOUND CARE BIOLOGICS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 51: CANADA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 52: CANADA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2016-2023 (USD MILLION)
  • TABLE 53: CANADA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 54: PREVALENCE OF DIABETES IN EUROPE, 2015-2040
  • TABLE 55: EUROPE: WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 56: EUROPE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 57: EUROPE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2016-2023 (USD MILLION)
  • TABLE 58: EUROPE: WOUND CARE BIOLOGICS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 59: UK: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 60: UK: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2016-2023 (USD MILLION)
  • TABLE 61: UK: WOUND CARE BIOLOGICS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 62: GERMANY: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 63: GERMANY: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2016-2023 (USD MILLION)
  • TABLE 64: GERMANY: WOUND CARE BIOLOGICS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 65: FRANCE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 66: FRANCE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2016-2023 (USD MILLION)
  • TABLE 67: FRANCE: WOUND CARE BIOLOGICS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 68: ROE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 69: ROE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2016-2023 (USD MILLION)
  • TABLE 70: ROE: WOUND CARE BIOLOGICS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 71: APAC: WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 72: APAC: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 73: APAC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2016-2023 (USD MILLION)
  • TABLE 74: APAC: WOUND CARE BIOLOGICS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 75: CHINA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 76: CHINA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2016-2023 (USD MILLION)
  • TABLE 77: CHINA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 78: JAPAN: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 79: JAPAN: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2016-2023 (USD MILLION)
  • TABLE 80: JAPAN: WOUND CARE BIOLOGICS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 81: ROAPAC: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 82: ROAPAC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2016-2023 (USD MILLION)
  • TABLE 83: ROAPAC: WOUND CARE BIOLOGICS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 84: ROW: DIABETIC POPULATION, BY REGION
  • TABLE 85: ROW: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 86: ROW: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2016-2023 (USD MILLION)
  • TABLE 87: ROW: WOUND CARE BIOLOGICS MARKET, BY END USER, 2016-2023 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1: GLOBAL WOUND CARE BIOLOGICS MARKET
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4: WOUND CARE BIOLOGICS MARKET: BOTTOM-UP APPROACH
  • FIGURE 5: WOUND CARE BIOLOGICS MARKET: TOP-DOWN APPROACH
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2018 VS. 2023 (USD BILLION)
  • FIGURE 8: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2018 VS. 2023 (USD BILLION)
  • FIGURE 9: WOUND CARE BIOLOGICS MARKET, BY END USER, 2018 VS. 2023 (USD BILLION)
  • FIGURE 10: WOUND CARE BIOLOGICS MARKET, BY REGION, 2018 VS. 2023 (USD BILLION)
  • FIGURE 11: HIGH PREVALENCE AND INCREASING INCIDENCE RATE OF DIABETIC FOOT ULCERS TO DRIVE MARKET GROWTH
  • FIGURE 12: BIOLOGICAL SKIN SUBSTITUTES TO DOMINATE THE NORTH AMERICAN WOUND CARE BIOLOGICS MARKET IN 2018
  • FIGURE 13: ASIA PACIFIC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 14: BIOLOGICAL SKIN SUBSTITUTES TO DOMINATE THE WOUND CARE BIOLOGICS MARKET DURING 2018 TO 2023
  • FIGURE 15: WOUND CARE BIOLOGICS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
  • FIGURE 16: INCIDENCE OF DIABETES, BY REGION (2015 VS. 2040)
  • FIGURE 17: BIOLOGICAL SKIN SUBSTITUTE SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 18: ULCERS SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 19: HOSPITALS ARE ESTIMATED TO BE THE LARGEST END USERS OF WOUND CARE BIOLOGICS IN 2018
  • FIGURE 20: NORTH AMERICA TO DOMINATE THE WOUND CARE BIOLOGICS MARKET IN 2018
  • FIGURE 21: NORTH AMERICA: WOUND CARE BIOLOGICS MARKET SNAPSHOT
  • FIGURE 22: WOUND PREVALENCE IN THE US (2013)
  • FIGURE 23: ASIA PACIFIC : WOUND CARE BIOLOGICS MARKET SNAPSHOT
  • FIGURE 24: PRODUCT LAUNCHES, THE MOST ADOPTED GROWTH STRATEGY FROM 2015 TO 2018
  • FIGURE 25: SMITH & NEPHEW: COMPANY SNAPSHOT
  • FIGURE 26: MOLNLYCKE HEALTH CARE AB (INVESTOR AB): COMPANY SNAPSHOT
  • FIGURE 27: INTEGRA LIFESCIENCES: COMPANY SNAPSHOT
  • FIGURE 28: WRIGHT MEDICAL: COMPANY SNAPSHOT
  • FIGURE 29: MIMEDX GROUP: COMPANY SNAPSHOT
  • FIGURE 30: VERICEL: COMPANY SNAPSHOT
  • FIGURE 31: ANIKA THERAPEUTICS: COMPANY SNAPSHOT
  • FIGURE 32: OSIRIS THERAPEUTICS: COMPANY SNAPSHOT